Global Fatty Acid Oxidation Disorder Market

Global Fatty Acid Oxidation Disorder Market Size, Trends, and Analysis - Forecasts To 2026 By Drug Type (Levocarnitine, Dextrose, Riboflavin, and Others), By Route of Administration (Oral and Intravenous), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Drug Stores, and Online Stores), By Region (North America, Asia Pacific, CSA, Europe, and the Middle East and Africa); End-User Landscape, Company Market Share Analysis & Competitor Analysis

Category Healthcare

Format

This report was recently updated on October 23 2024 with the latest and most recent market numbers

Global Fatty Acid Oxidation Disorder Market: Insights

The overall population is expected to reach 8.5 billion by 2030, leading to an increase in the worldwide consumption of numerous products. Expanding need for sustainable bio-products including soaps, food emulsifiers, surface cleaners, detergents, fertilizers, cosmetics, paints, and skincare items has raised the fatty acid market requirement for industrial commercial, and consumer use.

Because of their numerous health advantages, two essential polyunsaturated fatty acids (PUFAs), Omega-3 and Omega-6 fatty acids are well-known in the healthcare business. The medicinal acumen of fatty acids is attributed to their potential effectiveness in the treatment of heart disease, renal and lung disorders, blood pressure, and others when used as medications and nutritional supplements. Core demographics following imbalanced nutrition for a prolonged period of time aids in the market expansion of fatty acid oxidation disease.

The prevalence of fatty acid oxidation disease is 1 in 5,000-10,000 births worldwide, as per the National Institutes of Health (NIH). The rise in the incidence of rare and inherited diseases raises the market demand for disorders of fatty acid oxidation. Growing research and development investment from leading biopharmaceutical firms is anticipated to accelerate the growth of the demand for fatty acid oxidation disorders. For example, Ultragenyx Pharmaceutical Inc., a market player in developing drugs for rare disorders, reported in July 2020 that the U.S. Food and Drug Administration (FDA) authorized triheptanoin, a new drug used in the therapy of fatty acid oxidation disorder. A lack of understanding of available treatment alternatives for rare diseases is expected to impede the development of the market for fatty acid oxidation disorders. A challenging part for fatty acid oxidation disorder industry growth is the strict regulatory requirement for approving the drug.

global fatty acid oxidation disorder market

Global Fatty Acid Oxidation Disorder Market: By Drug Type

Based on drug type, the market has been categorized into levocarnitine, dextrose, riboflavin, and others. Levocarnitine has the highest share in the fatty acid oxidation disorder market with a large demand. Levocarnitine (L-Carnitine) is a molecule essential for the metabolic processes of mammalian energy, which eliminates harmful acyl chemicals from the cell walls to sustain a stable metabolic rate. It is an amino acid that can be synthesized within the body spontaneously and helps to provide nutrition for the body. It enables the transfer of long-chain fatty acids for beta-oxidation and energy production through mitochondria. Growing incidences of Rett syndrome, anorexia, thyroid, cardiovascular disorders, and diabetes are predicted to have a positive effect on increasing demand for levocarnitine for its use in the pharmaceutical industry and hence the market size of levocarnitine is likely to produce substantial growth throughout the forecast period. The rising global geriatric population base, combined with an increasing customer proclivity to health awareness, will encourage the growth of the levocarnitine segment.

Global Fatty Acid Oxidation Disorder Market: By Route of Administration

Based on the route of administration, the market has been segmented into oral and intravenous drugs. In the fatty acid oxidation disorder market, oral drugs are most predominant, creating maximum profits. Many drugs, such as liquids, capsules, tablets, or chewable tablets, can be taken orally. Since the oral route is the most accessible and generally the safest and least costly, it is the one most commonly used. However, it has drawbacks since the manner in which a drug usually passes through the digestive system. Whereas, with the development of injectable medications in the fatty acid oxidation disorder market, intravenous routes of administration would see a substantial increase in demand.

Global Fatty Acid Oxidation Disorder Market: By Distribution Channel

Based on the distribution channel, the market is categorized as hospital pharmacies, retail pharmacies, drug stores, and online stores. Hospital pharmacies hold the major proportion among the distribution channel in the fatty acid oxidation disorder market. The increasing aging population, expanding disposable income, evolving medical conditions, and the advent of new diseases help to raise the demand for different drugs which in turn is expanding the hospital pharmacy segment. In addition to the aging and growing population, the development of the pharmaceutical industry is also motivated by the increase in the spending power and access to affordable healthcare and pharmaceuticals for low and middle-class families.

The online pharmacy would also see a large surge in demand with an augmented retail footprint in the fatty acid oxidation disorder market. Improved access to high-speed internet and growing mobile usage has made it possible to access e-commerce websites. The major advantages provided by online pharmacies to customers are ease of use, home delivery of drugs, no fear of spurious medicines, and discounts provided on the medicines.

asia pacific fatty acid oxidation disorder market

Global Fatty Acid Oxidation Disorder Market: By Region

With a high rate of acceptance and commercialization, North America is projected to lead the fatty acid oxidation condition market throughout the forecast period. The regional market players provide a comprehensive selection of fatty acids, including distilled and polymerized fatty acids, stearic fatty acids, and many more, by using ecological energy resources to make these solutions. The rising number of inherited and rare disorders makes the demand for fatty acid oxidation disorders attractive in Europe. With rising domestic producers, Asia-Pacific is projected to experience the fastest growth rate in the fatty acid oxidation disorder market in the near future. Increased diagnostic and treatment-seeking rates in the Asia-Pacific population make it profitable for the development of the market for fatty acid oxidation disorder. With relatively low healthcare spending and weak economic conditions, the Middle East and Africa are less profitable in the demand for fatty acid oxidation disorders.

Global Fatty Acid Oxidation Disorder Market: Share & Competitor Analysis

Northeast Pharmaceutical Group Co., Ltd., Sigma-Tau Pharmaceuticals, Bedford Laboratories, Merck KGaA, AminoScience LLC, Chengda Pharmaceuticals Co. Ltd., Biosynth AG, Mylan Laboratories Limited, Spectrum Chemicals, Daiichi Sankyo Ltd., and Colgate Palmolive Ltd are the major vendors competing in the fatty acid oxidation disorder market.

Please note: This is not an exhaustive list of companies profiled in the report.

Chapter 1 Methodology

1.1 Market Scope & Definitions

1.2 Estimates & Forecast Calculation

1.3 Historical Data Overview And Validation

1.4 Data Drug Types

1.4.1 Secondary

1.4.2 Primary

Chapter 2 Report Outlook

2.1 Global Fatty Acid Oxidation Disorder Industry Overview, 2016-2026

2.1.1 Industry Overview

2.1.2 Drug Type Overview

2.1.3 Route of Administration Overview

2.1.4 Distribution Channel Overview

2.1.5 Regional Overview

Chapter 3 Global Fatty Acid Oxidation Disorder Market Trends

3.1 Market Segmentation

3.2 Industry Background, 2016-2026

3.3 Market Key Trends

3.3.1 Positive Trends

3.3.1.1 Rising Prevalence of Rare and Genetic Disorders

3.3.1.2 Increasing Funding for Research and Development From Leading Biopharmaceutical Companies

3.3.2 Industry Challenges

3.3.2.1 Lack of Awareness About Therapeutic Options Available For Rare Disorders

3.4 Prospective Growth Scenario

3.4.1 Drug Type Growth Scenario

3.4.2 Route of Administration Growth Scenario

3.4.3 Distribution Channel Growth Scenario

3.5 COVID-19 Influence over Industry Growth

3.6 Porter’s Analysis

3.7 PESTEL Analysis

3.8 Value Chain & Supply Chain Analysis

3.9 Regulatory Framework

3.9.1 North America

3.9.2 Europe

3.9.3 APAC

3.9.4 LATAM

3.9.5 MEA

3.10 Technology Overview

3.11 Market Share Analysis, 2020

3.11.1 Company Positioning Overview, 2020

Chapter 4 Global Fatty Acid Oxidation Disorder Market, By Drug Type

4.1 Drug Type Outlook

4.2 Levocarnitine

4.2.1 Market Size, By Region, 2016-2026 (USD Million)

4.3 Dextrose

4.3.1 Market Size, By Region, 2016-2026 (USD Million)

4.4 Riboflavin

4.4.1 Market Size, By Region, 2016-2026 (USD Million)

4.5 Others

4.5.1 Market Size, By Region, 2016-2026 (USD Million)

Chapter 5 Global Fatty Acid Oxidation Disorder Market, By Route of Administration

5.1 Route of Administration Outlook

5.2 Oral

5.2.1 Market Size, By Region, 2016-2026 (USD Million)

5.3 Intravenous

5.3.1 Market Size, By Region, 2016-2026 (USD Million)

Chapter 6 Global Fatty Acid Oxidation Disorder Market, By Distribution Channel

6.1 Distribution Channel Outlook

6.2 Hospital Pharmacies

6.2.1 Market Size, By Region, 2016-2026 (USD Million)

6.3 Retail Pharmacies

6.3.1 Market Size, By Region, 2016-2026 (USD Million)

6.4 Drug Stores

6.4.1 Market Size, By Region, 2016-2026 (USD Million)

6.5 Online Stores

6.5.1 Market Size, By Region, 2016-2026 (USD Million)

Chapter 7 Global Fatty Acid Oxidation Disorder Market, By Region

7.1 Regional outlook

7.2 North America

7.2.1 Market Size, By Country, 2016-2026 (USD Million)

7.2.2 Market Size, By Drug Type, 2016-2026 (USD Million)

7.2.3 Market Size, By Route of Administration, 2016-2026 (USD Million)

7.2.4 Market Size, By Distribution Channel, 2016-2026 (USD Million)

7.2.5 U.S.

7.2.5.1 Market Size, By Drug Type, 2016-2026 (USD Million)

7.2.5.2 Market Size, By Route of Administration, 2016-2026 (USD Million)

7.2.5.3 Market Size, By Distribution Channel, 2016-2026 (USD Million)

7.2.6 Canada

7.2.6.1 Market Size, By Drug Type, 2016-2026 (USD Million)

7.2.6.2 Market Size, By Route of Administration, 2016-2026 (USD Million)

7.2.6.3 Market Size, By Distribution Channel, 2016-2026 (USD Million)

7.3 Europe

7.3.1 Market Size, By Country, 2016-2026 (USD Million)

7.3.2 Market Size, By Drug Type, 2016-2026 (USD Million)

7.3.3 Market Size, By Route of Administration, 2016-2026 (USD Million)

7.3.4 Market Size, By Distribution Channel, 2016-2026 (USD Million)

7.3.5 Germany

7.3.5.1 Market Size, By Drug Type, 2016-2026 (USD Million)

7.3.5.2 Market Size, By Route of Administration, 2016-2026 (USD Million)

7.3.5.3 Market Size, By Distribution Channel, 2016-2026 (USD Million)

7.3.6 UK

7.3.6.1 Market Size, By Drug Type, 2016-2026 (USD Million)

7.3.6.2 Market Size, By Route of Administration, 2016-2026 (USD Million)

7.3.6.3 Market Size, By Distribution Channel, 2016-2026 (USD Million)

7.3.7 France

7.3.7.1 Market Size, By Drug Type, 2016-2026 (USD Million)

7.3.7.2 Market Size, By Route of Administration, 2016-2026 (USD Million)

7.3.7.3 Market Size, By Distribution Channel, 2016-2026 (USD Million)

7.3.8 Italy

7.3.8.1 Market Size, By Drug Type, 2016-2026 (USD Million)

7.3.8.2 Market Size, By Route of Administration, 2016-2026 (USD Million)

7.3.8.3 Market Size, By Distribution Channel, 2016-2026 (USD Million)

7.3.9 Spain

7.3.9.1 Market Size, By Drug Type, 2016-2026 (USD Million)

7.3.9.2 Market Size, By Route of Administration, 2016-2026 (USD Million)

7.3.9.3 Market Size, By Distribution Channel, 2016-2026 (USD Million)

7.3.10 Russia

7.3.10.1 Market Size, By Drug Type, 2016-2026 (USD Million)

7.3.10.2 Market Size, By Route of Administration, 2016-2026 (USD Million)

7.3.10.3 Market Size, By Distribution Channel, 2016-2026 (USD Million)

7.4 Asia Pacific

7.4.1 Market Size, By Country, 2016-2026 (USD Million)

7.4.2 Market Size, By Drug Type, 2016-2026 (USD Million)

7.4.3 Market Size, By Route of Administration, 2016-2026 (USD Million)

7.4.4 Market Size, By Distribution Channel, 2016-2026 (USD Million)

7.4.5 China

7.4.5.1 Market Size, By Drug Type, 2016-2026 (USD Million)

7.4.5.2 Market Size, By Route of Administration, 2016-2026 (USD Million)

7.4.5.3 Market Size, By Distribution Channel, 2016-2026 (USD Million)

7.4.6 India

7.4.6.1 Market Size, By Drug Type, 2016-2026 (USD Million)

7.4.6.2 Market Size, By Route of Administration, 2016-2026 (USD Million)

7.4.6.3 Market Size, By Distribution Channel, 2016-2026 (USD Million)

7.4.7 Japan

7.4.7.1 Market Size, By Drug Type, 2016-2026 (USD Million)

7.4.7.2 Market Size, By Route of Administration, 2016-2026 (USD Million)

7.4.7.3 Market Size, By Distribution Channel, 2016-2026 (USD Million)

7.4.8 Australia

7.4.8.1 Market Size, By Drug Type, 2016-2026 (USD Million)

7.4.8.2 Market size, By Route of Administration, 2016-2026 (USD Million)

7.4.8.3 Market Size, By Distribution Channel, 2016-2026 (USD Million)

7.4.9 South Korea

7.4.9.1 Market Size, By Drug Type, 2016-2026 (USD Million)

7.4.9.2 Market Size, By Route of Administration, 2016-2026 (USD Million)

7.4.9.3 Market Size, By Distribution Channel, 2016-2026 (USD Million)

7.5 Latin America

7.5.1 Market Size, By Country, 2016-2026 (USD Million)

7.5.2 Market Size, By Drug Type, 2016-2026 (USD Million)

7.5.3 Market Size, By Route of Administration, 2016-2026 (USD Million)

7.5.4 Market Size, By Distribution Channel, 2016-2026 (USD Million)

7.5.5 Brazil

7.5.5.1 Market Size, By Drug Type, 2016-2026 (USD Million)

7.5.5.2 Market Size, By Route of Administration, 2016-2026 (USD Million)

7.5.5.3 Market Size, By Distribution Channel, 2016-2026 (USD Million)

7.5.6 Mexico

7.5.6.1 Market Size, By Drug Type, 2016-2026 (USD Million)

7.5.6.2 Market Size, By Route of Administration, 2016-2026 (USD Million)

7.5.6.3 Market Size, By Distribution Channel, 2016-2026 (USD Million)

7.5.7 Argentina

7.5.7.1 Market Size, By Drug Type, 2016-2026 (USD Million)

7.5.7.2 Market Size, By Route of Administration, 2016-2026 (USD Million)

7.5.7.3 Market Size, By Distribution Channel, 2016-2026 (USD Million)

7.6 MEA

7.6.1 Market Size, By Country, 2016-2026 (USD Million)

7.6.2 Market Size, By Drug Type, 2016-2026 (USD Million)

7.6.3 Market Size, By Route of Administration, 2016-2026 (USD Million)

7.6.4 Market Size, By Distribution Channel, 2016-2026 (USD Million)

7.6.5 Saudi Arabia

7.6.5.1 Market Size, By Drug Type, 2016-2026 (USD Million)

7.6.5.2 Market Size, By Route of Administration, 2016-2026 (USD Million)

7.6.5.3 Market Size, By Distribution Channel, 2016-2026 (USD Million)

7.6.6 UAE

7.6.6.1 Market Size, By Drug Type, 2016-2026 (USD Million)

7.6.6.2 Market Size, By Route of Administration, 2016-2026 (USD Million)

7.6.6.3 Market Size, By Distribution Channel, 2016-2026 (USD Million)

7.6.7 South Africa

7.6.7.1 Market Size, By Drug Type, 2016-2026 (USD Million)

7.6.7.2 Market Size, By Route of Administration, 2016-2026 (USD Million)

7.6.7.3 Market Size, By Distribution Channel, 2016-2026 (USD Million)

Chapter 8 Company Landscape

8.1 Competitive Analysis, 2020

8.2 Northeast Pharmaceutical Group Co., Ltd.

8.2.1 Company Overview

8.2.2 Financial Analysis

8.2.3 Strategic Positioning

8.2.4 Info Graphic Analysis

8.3 Sigma-Tau Pharmaceuticals

8.3.1 Company Overview

8.3.2 Financial Analysis

8.3.3 Strategic Positioning

8.3.4 Info Graphic Analysis

8.4 Bedford Laboratories

8.4.1 Company Overview

8.4.2 Financial Analysis

8.4.3 Strategic Positioning

8.4.4 Info Graphic Analysis

8.5 Merck KGaA

8.5.1 Company Overview

8.5.2 Financial Analysis

8.5.3 Strategic Positioning

8.5.4 Info Graphic Analysis

8.6 AminoScience LLC

8.6.1 Company Overview

8.6.2 Financial Analysis

8.6.3 Strategic Positioning

8.6.4 Info Graphic Analysis

8.7 Chengda Pharmaceuticals Co. Ltd.

8.7.1 Company Overview

8.7.2 Financial Analysis

8.7.3 Strategic Positioning

8.7.4 Info Graphic Analysis

8.8 Biosynth AG

8.8.1 Company Overview

8.8.2 Financial Analysis

8.8.3 Strategic Positioning

8.8.4 Info Graphic Analysis

8.9 Mylan Laboratories Limited

8.9.1 Company Overview

8.9.2 Financial Analysis

8.9.3 Strategic Positioning

8.9.4 Info Graphic Analysis

8.10 Spectrum Chemicals

8.10.1 Company Overview

8.10.2 Financial Analysis

8.10.3 Strategic Positioning

8.10.4 Info Graphic Analysis

8.11 Daiichi Sankyo Ltd.

8.11.1 Company Overview

8.11.2 Financial Analysis

8.11.3 Strategic Positioning

8.11.4 Info Graphic Analysis

8.12 Colgate Palmolive Ltd

8.12.1 Company Overview

8.12.2 Financial Analysis

8.12.3 Strategic Positioning

8.12.4 Info Graphic Analysis

8.13 Other Companies

8.13.1 Company Overview

8.13.2 Financial Analysis

8.13.3 Strategic Positioning

8.13.4 Info Graphic Analysis

The Global Fatty Acid Oxidation Disorder Market has been studied from the year 2019 till 2026. However, the CAGR provided in the report is from the year 2021 to 2026. The research methodology involved three stages: Desk research, Primary research, and Analysis & Output from the entire research process.

The desk research involved a robust background study which meant referring to paid and unpaid databases to understand the market dynamics; mapping contracts from press releases; identifying the key players in the market, studying their product portfolio, competition level, annual reports/SEC filings & investor presentations; and learning the demand and supply-side analysis for the Fatty Acid Oxidation Disorder Market.

The primary research activity included telephonic conversations with more than 50 tier 1 industry consultants, distributors, and end-use product manufacturers.

Finally, based on the above thorough research process, an in-depth analysis was carried out considering the following aspects: market attractiveness, current & future market trends, market share analysis, SWOT analysis of the company and customer analytics.

We value your investment and offer free customization with every report to fulfil your exact research needs.

This website is secure and your personal details are safe. Privacy

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

What is the projected market size of the global fatty acid oxidation disorder market?

The global fatty acid oxidation disorder market size is projected to grow at a CAGR of 4% during the forecast period (2021-2026).

Who are the major vendors in the fatty acid oxidation disorder market?

Key and innovative vendors in the fatty acid oxidation disorder market include Northeast Pharmaceutical Group Co., Ltd., Sigma-Tau Pharmaceuticals, Bedford Laboratories, Merck KGaA, AminoScience LLC, Chengda Pharmaceuticals Co. Ltd., Biosynth AG, Mylan Laboratories Limited, Spectrum Chemicals, Daiichi Sankyo Ltd., and Colgate Palmolive Ltd.

Which region has the highest market share in the fatty acid oxidation disorder market?

North America is estimated to hold the highest market share in the fatty acid oxidation disorder market.

What is the Covid-19 impact on future fatty acid oxidation disorder manufacturers?

Globally, Covid-19 impact on the future fatty acid oxidation disorder market will be quite significant for the manufacturers since demand has fluctuated owing to lockdown in key nations throughout the world. North America would be leading because of the rising number of inherited and rare disorders. Subsequently, the Asia Pacific market will be growing the fastest because of the expanding diagnostic and treatment-seeking rates.

What are the major drivers in the fatty acid oxidation disorder market?

The major driving factors for the fatty acid oxidation disorder market include the augmenting need for sustainable bio-products; increasing R&D activities; rising incidence of rare and inherited diseases raises; growing awareness about the numerous health advantages of fatty acid.